Artificial Intelligence

Longevity’s Great Experiment

The longevity market is booming, but does more medicine make us healthier?

Posted September 16, 2026

Longevity certainly seems to be the word of the day. There are longevity clinics, longevity conferences, longevity experts, longevity supplements, and a mind-bending collection of tests and technologies designed to drive both life extension and life expansion.

Of course, there's something very “vital” about the idea. Medicine has traditionally waited for something to go wrong, and longevity flips that model around. The idea is to measure earlier. And look deeper to find risk before it becomes disease. And increasingly, intervene before the problem even arrives—finding “stage zero” disease. And as medicine pushes to earlier and earlier detection, it might find itself adjacent to the elusive goal of prevention.

But there's a basic question hiding underneath all this enthusiasm. How much of what we now call longevity medicine is established medicine?

From Prevention to Prediction

A good deal of longevity medicine is conventional and well established. Things like exercise, maintaining bone and muscle mass, controlling blood pressure and cholesterol, avoiding smoking and managing metabolic disease aren't particularly cutting edge. And they have years of evidence behind them.

Today, longevity medicine has expanded the options. Whole-body MRI, biomarkers, genomic sequencing, disease risk scores, biological age testing and continuous monitoring (think blood sugar and heart rate) are becoming viable options. Then there are interventions including peptides, hormones, various drugs and regenerative approaches such as stem-cell therapies. All of these are entering the dialogue—from the physician’s office to the dining room table.

The issue here is that these don't all carry the same level of proof. Whole-body MRI, for example, can certainly find abnormalities in asymptomatic people, but recent reviews continue to question the routine use, particularly in average-risk populations. The medical literature also continues to advocate for “less hype and more clinical evidence” for longevity interventions.

So, some longevity interventions are being evaluated in real time, or perhaps better said as in our "life" time. Our ability to measure, predict, and even intervene in biological activity that may impact aging may be advancing faster than the evidence that these interventions can extend the length or quality of life.

How Much Medicine Is Enough?

This raises another question that I find particularly interesting. Medicine understands dose-response relationships very well when we're talking about drugs. Take too little and the drug may not work. Increase the dose and the benefit may increase. Eventually the curve can flatten, and at some point, higher does can become toxic.

But what's the dose-response curve for medicine itself?

In this case, the “dose” is the amount of clinical attention directed toward a person over a specific period of time. Conventional medicine is rather low dose, particularly for people who aren't sick or are asymptomatic. A physical, a few office visits, a few recommended (but often avoided) screenings and some blood work might be the typical plan for a healthy person.

A real-world example is Radence, a new company that is tackling longevity with a data-rich and human-touch plan. About six months after launch, the company says it has approximately 50 members. Each receives 120 to 180 hours of multidisciplinary clinical attention per year. This includes physicians, nurse practitioners, pharmacists and genetic counselors. Further, members are assessed across more than 150 biomarkers and receive genomic analysis involving nearly 3,000 genes, along with advanced imaging, wearable data and home monitoring. The average member also receives about five specialist referrals each year.

That's an extraordinary amount of time, data and medicine directed toward someone who may not consider himself or herself sick. And that's precisely what makes it interesting.

Finding More Isn't the Same as Living Longer

Radence isn't simply collecting data. They are using AI to identify key insights, while physicians decide what is clinically meaningful. My sense is that this two-pronged approach is essential given today’s clinical uncertainties.

That may represent an important evolution in longevity medicine. The challenge isn't simply acquiring more biological information. It's deciding what to do to whom. Julie Chen, MD, the company’s chief medical officer, highlights the importance of actionable data.

"The goal isn't simply to generate more data or find more abnormalities. The challenge is determining which signals are clinically meaningful and which warrant action."

But a larger question remains. If we look harder at healthy people, we will certainly find more things. More findings can mean more testing, more specialists and more interventions. Some of those interventions may save lives. Others may simply drive higher clinical utilization and costs.

Longevity's Real Experiment

More doesn't make longevity medicine misguided. In fact, the opposite possibility deserves serious consideration. Traditional healthcare may devote far too little attention to prevention and the biological changes that precede disease. Perhaps much a “higher dose” of clinical attention—both human and technological—will uncover disease or dysfunction early enough to change outcomes.

And that may be longevity's most interesting experiment. It isn't simply whether science can extend human life or whether AI can predict disease years before symptoms appear. We are also beginning to test something interesting about care itself. How much medicine does a healthy human actually need?

The future of longevity may not belong to maximum medicine but to discovering the optimal dose of care itself.

Read the original article on Psychology Today →